Fundraisings and IPOs

Date: 2021-04-13

Type of information: IPO

Company: Vectivbio (Switzerland)


Amount: $146.6 million

Funding type: IPO

Planned used:


  • On April 13, 2021, VectivBio, a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need,  announced the closing of its initial public offering of 8,625,000 ordinary shares, which includes the full exercise of the underwriters’ option to purchase an additional 1,125,000 ordinary shares, at a public offering price of $17.00 per share. The gross proceeds from the offering were approximately $146.6 million. Vectiv’s ordinary shares began trading on the Nasdaq Global Market under the ticker symbol “VECT” on April 9, 2021. All of the ordinary shares were offered by Vectiv. BofA Securities, SVB Leerink and Credit Suisse acted as joint book-running managers for the offering. LifeSci Capital also acted as an underwriter for the offering.
  • On April 8, 2021, VectivBio announced the pricing of its initial public offering of 7,500,000 ordinary shares at a public offering price of $17.00 per share. The gross proceeds to Vectiv, before deducting underwriting discounts and commissions and offering expenses, are expected to be $127.5 million. All of the ordinary shares are being offered by Vectiv. In addition, Vectiv has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 ordinary shares at the initial public offering price, less the underwriting discounts and commissions.

Therapeutic area: Inflammatory diseases - Gastrointestinal diseases - Transplantation

Is general: Yes